vs
徕博科（LH）与Masco（MAS）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是Masco的2.0倍（$3.5B vs $1.8B），Masco净利率更高（9.2% vs 4.7%，领先4.5%），徕博科同比增速更快（5.6% vs -1.9%），徕博科自由现金流更多（$490.3M vs $371.0M），过去两年徕博科的营收复合增速更高（5.2% vs -3.5%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
LH vs MAS — 直观对比
营收规模更大
LH
是对方的2.0倍
$1.8B
营收增速更快
LH
高出7.5%
-1.9%
净利率更高
MAS
高出4.5%
4.7%
自由现金流更多
LH
多$119.3M
$371.0M
两年增速更快
LH
近两年复合增速
-3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $1.8B |
| 净利润 | $164.7M | $165.0M |
| 毛利率 | 28.2% | 33.9% |
| 营业利润率 | 7.6% | 13.8% |
| 净利率 | 4.7% | 9.2% |
| 营收同比 | 5.6% | -1.9% |
| 净利润同比 | 14.9% | -9.3% |
| 每股收益（稀释后） | $1.98 | $0.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHMAS
| Q4 25 | $3.5B | $1.8B | ||
| Q3 25 | $3.6B | $1.9B | ||
| Q2 25 | $3.5B | $2.1B | ||
| Q1 25 | $3.3B | $1.8B | ||
| Q4 24 | $3.3B | $1.8B | ||
| Q3 24 | $3.3B | $2.0B | ||
| Q2 24 | $3.2B | $2.1B | ||
| Q1 24 | $3.2B | $1.9B |
净利润LHMAS
| Q4 25 | $164.7M | $165.0M | ||
| Q3 25 | $261.1M | $189.0M | ||
| Q2 25 | $237.9M | $270.0M | ||
| Q1 25 | $212.8M | $186.0M | ||
| Q4 24 | $143.4M | $182.0M | ||
| Q3 24 | $169.3M | $167.0M | ||
| Q2 24 | $205.3M | $258.0M | ||
| Q1 24 | $228.0M | $215.0M |
毛利率LHMAS
| Q4 25 | 28.2% | 33.9% | ||
| Q3 25 | 28.8% | 34.2% | ||
| Q2 25 | 29.7% | 37.6% | ||
| Q1 25 | 28.3% | 35.8% | ||
| Q4 24 | 26.9% | 34.8% | ||
| Q3 24 | 27.6% | 36.6% | ||
| Q2 24 | 28.8% | 37.5% | ||
| Q1 24 | 28.2% | 35.6% |
营业利润率LHMAS
| Q4 25 | 7.6% | 13.8% | ||
| Q3 25 | 11.1% | 15.8% | ||
| Q2 25 | 11.2% | 20.1% | ||
| Q1 25 | 9.7% | 15.9% | ||
| Q4 24 | 6.5% | 15.9% | ||
| Q3 24 | 7.7% | 18.0% | ||
| Q2 24 | 9.2% | 19.0% | ||
| Q1 24 | 10.1% | 16.5% |
净利率LHMAS
| Q4 25 | 4.7% | 9.2% | ||
| Q3 25 | 7.3% | 9.9% | ||
| Q2 25 | 6.7% | 13.2% | ||
| Q1 25 | 6.4% | 10.3% | ||
| Q4 24 | 4.3% | 10.0% | ||
| Q3 24 | 5.2% | 8.4% | ||
| Q2 24 | 6.4% | 12.3% | ||
| Q1 24 | 7.2% | 11.2% |
每股收益（稀释后）LHMAS
| Q4 25 | $1.98 | $0.81 | ||
| Q3 25 | $3.12 | $0.90 | ||
| Q2 25 | $2.84 | $1.28 | ||
| Q1 25 | $2.52 | $0.87 | ||
| Q4 24 | $1.72 | $0.85 | ||
| Q3 24 | $2.00 | $0.77 | ||
| Q2 24 | $2.43 | $1.17 | ||
| Q1 24 | $2.69 | $0.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $647.0M |
| 总债务越低越好 | — | $2.9B |
| 股东权益账面价值 | $8.6B | $-185.0M |
| 总资产 | $18.4B | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LHMAS
| Q4 25 | $532.3M | $647.0M | ||
| Q3 25 | $598.1M | $559.0M | ||
| Q2 25 | $647.3M | $390.0M | ||
| Q1 25 | $369.4M | $377.0M | ||
| Q4 24 | $1.5B | $634.0M | ||
| Q3 24 | $1.5B | $646.0M | ||
| Q2 24 | $265.1M | $398.0M | ||
| Q1 24 | $99.3M | $368.0M |
总债务LHMAS
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LHMAS
| Q4 25 | $8.6B | $-185.0M | ||
| Q3 25 | $8.7B | $-78.0M | ||
| Q2 25 | $8.5B | $-84.0M | ||
| Q1 25 | $8.3B | $-254.0M | ||
| Q4 24 | $8.1B | $-279.0M | ||
| Q3 24 | $8.2B | $-88.0M | ||
| Q2 24 | $8.0B | $-26.0M | ||
| Q1 24 | $8.0B | $-75.0M |
总资产LHMAS
| Q4 25 | $18.4B | $5.2B | ||
| Q3 25 | $18.3B | $5.3B | ||
| Q2 25 | $18.1B | $5.3B | ||
| Q1 25 | $17.6B | $5.1B | ||
| Q4 24 | $18.4B | $5.0B | ||
| Q3 24 | $18.6B | $5.3B | ||
| Q2 24 | $16.7B | $5.4B | ||
| Q1 24 | $16.5B | $5.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $418.0M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $371.0M |
| 自由现金流率自由现金流/营收 | 13.9% | 20.7% |
| 资本支出强度资本支出/营收 | 3.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.73× | 2.53× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $866.0M |
8季度趋势，按日历期对齐
经营现金流LHMAS
| Q4 25 | $614.2M | $418.0M | ||
| Q3 25 | $387.2M | $456.0M | ||
| Q2 25 | $620.6M | $306.0M | ||
| Q1 25 | $18.5M | $-158.0M | ||
| Q4 24 | $777.2M | $407.0M | ||
| Q3 24 | $277.3M | $416.0M | ||
| Q2 24 | $561.1M | $346.0M | ||
| Q1 24 | $-29.8M | $-94.0M |
自由现金流LHMAS
| Q4 25 | $490.3M | $371.0M | ||
| Q3 25 | $280.5M | $415.0M | ||
| Q2 25 | $542.7M | $270.0M | ||
| Q1 25 | $-107.5M | $-190.0M | ||
| Q4 24 | $665.1M | $351.0M | ||
| Q3 24 | $161.5M | $378.0M | ||
| Q2 24 | $432.9M | $303.0M | ||
| Q1 24 | $-163.6M | $-125.0M |
自由现金流率LHMAS
| Q4 25 | 13.9% | 20.7% | ||
| Q3 25 | 7.9% | 21.6% | ||
| Q2 25 | 15.4% | 13.2% | ||
| Q1 25 | -3.2% | -10.5% | ||
| Q4 24 | 20.0% | 19.2% | ||
| Q3 24 | 4.9% | 19.1% | ||
| Q2 24 | 13.4% | 14.5% | ||
| Q1 24 | -5.2% | -6.5% |
资本支出强度LHMAS
| Q4 25 | 3.5% | 2.6% | ||
| Q3 25 | 3.0% | 2.1% | ||
| Q2 25 | 2.2% | 1.8% | ||
| Q1 25 | 3.8% | 1.8% | ||
| Q4 24 | 3.4% | 3.1% | ||
| Q3 24 | 3.5% | 1.9% | ||
| Q2 24 | 4.0% | 2.1% | ||
| Q1 24 | 4.2% | 1.6% |
现金转化率LHMAS
| Q4 25 | 3.73× | 2.53× | ||
| Q3 25 | 1.48× | 2.41× | ||
| Q2 25 | 2.61× | 1.13× | ||
| Q1 25 | 0.09× | -0.85× | ||
| Q4 24 | 5.42× | 2.24× | ||
| Q3 24 | 1.64× | 2.49× | ||
| Q2 24 | 2.73× | 1.34× | ||
| Q1 24 | -0.13× | -0.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
MAS
| Plumbing Products | $844.0M | 47% |
| Decorative Architectural Products | $545.0M | 30% |
| Other | $404.0M | 23% |
